SCHEMBL5620125

SCHEMBL5620125

O=C(O)NCC1(C(F)(F)F)CC1

nearest known ligand 0.38

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.38
P2RX7 Q99572 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31174734 0.81 TSHR (0.42) DGAT1
SCHEMBL24756928 0.78 MEN1 (0.39) DGAT1
SCHEMBL23547605 0.76 SLC6A2 (0.31) P2RX7
SCHEMBL31174765 0.74 TSHR (0.40) DGAT1
SCHEMBL21245090 0.74 CA3 (0.38) DGAT1
SCHEMBL21244929 0.71 CA3 (0.43) DGAT1
SCHEMBL25944873 0.70 GNAI3 (0.43)
SCHEMBL16877059 0.70 CYP2C19 (0.38) DGAT1
SCHEMBL23194516 0.68
SCHEMBL21244607 0.68 LMNA (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1673347-B1 SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-08-19 EP claimed
CN-1894217-B Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors HOFFMANN LA ROCHE 2011-09-21 CN claimed
US-7166587-B2 Carbamic acid alkyl ester derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-23 US claimed
CN-1894217-A Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors HOFFMANN LA ROCHE (CH) 2007-01-10 CN claimed
US-20050075327-A1 Carbamic acid alkyl ester derivatives HOFFMAN-LA ROCHE INC. 2005-04-07 US claimed
EP-1673347-B1 SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-08-19 EP disclosed
CN-1894217-B Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors HOFFMANN LA ROCHE 2011-09-21 CN disclosed
US-7166587-B2 Carbamic acid alkyl ester derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-23 US disclosed
CN-1894217-A Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors HOFFMANN LA ROCHE (CH) 2007-01-10 CN disclosed
US-20050075327-A1 Carbamic acid alkyl ester derivatives HOFFMAN-LA ROCHE INC. 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075327-A1 Carbamic acid alkyl ester derivatives BCHE, CHRM1, ADCY7 DGAT1 1558/4885P2RX7 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.